Peptide Profile
Myristoyl Pentapeptide-17
Keratin-stimulating lipopeptide specifically designed to enhance eyelash and eyebrow growth through hair follicle activation.
Dose Range
0.01%-0.15%%
Frequency
Once daily
Route
Topical
Cycle Length
Ongoing/indefinite
Onset
Moderate (1-2 weeks)
Evidence
Limited
Compound Profile
Scientific & Efficacy Data
C41H81N9O6
Molecular Formula
796.2 Da
Molecular Weight
Topical application; sustained follicular activity with daily reapplication
Half-Life
Enhanced follicular penetration via myristic acid (C14) lipid conjugation
Bioavailability
959610-30-1
CAS #
127264611
PubChem ID ↗
Developed By · 2008
Collaborative cosmetic peptide research
Multiple cosmetic ingredient companies
Primary Benefits
Clinical observations show 25% lash length increase in 14 days and up to 72% by 6 weeks through targeted keratin gene stimulation in follicular cells.
Enhanced keratin synthesis increases hair shaft structural integrity, reducing lash breakage and improving overall resilience.
Exceptional safety record with no iris pigmentation changes, periorbital fat loss, or serious adverse effects — unlike prostaglandin-based alternatives.
Amino Acid Sequence
Myr-Lys-Leu-Ala-Lys-Lys-NH2 (myristoylated pentapeptide with C-terminal amide)Dosing
How much
do I take?
Timing
Best time to take
Apply Myristoyl Pentapeptide-17 to clean, dry skin. For best results, use consistently at the same time(s) each day. Evening application is often preferred to allow overnight absorption, unless otherwise directed.
With food?
As a topical product, Myristoyl Pentapeptide-17 is not affected by food intake. Apply to clean skin and allow adequate absorption time before covering the area.
If stacking
Myristoyl Pentapeptide-17 should be used as directed by your healthcare provider. If combining with other medications or supplements, discuss potential interactions with your provider. Avoid combining with compounds that have overlapping mechanisms unless specifically guided by a medical professional.
Adjusting Your Dose
Increase if
- +You've tolerated the current dose for the recommended period without significant side effects
- +Therapeutic goals haven't been met at the current dose level
- +Your healthcare provider recommends dose escalation based on your response
- +Lab work or clinical assessments support a higher dose
Decrease if
- -Side effects are bothersome or impacting daily life despite management strategies
- -You experience any signs of an adverse reaction
- -Lab results indicate the need for dose reduction
- -Your healthcare provider recommends a lower dose based on your response
Signs of right dose
- ✓Therapeutic goals being met with minimal side effects
- ✓Stable and consistent response to treatment
- ✓Lab values or clinical markers trending in the right direction
- ✓Good tolerance with manageable or absent side effects
Dosing Calculator
Calculate Your Exact Dose
Step 1: Peptide Weight
Find the weight printed on your peptide vial label
Look here!
The peptide weight is printed on the label
Look here!
The weight is on the label
Suitability
Is this
right for me?
Best For
Individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on individuals seeking longer, fuller eyelashes without prostaglandin-based prescriptions. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Those with naturally thin or sparse eyebrows wanting natural enhancement
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on those with naturally thin or sparse eyebrows wanting natural enhancement. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
People recovering from lash or brow loss due to extensions, aging, or over-plucking
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on people recovering from lash or brow loss due to extensions, aging, or over-plucking. Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Users wanting a gentle peptide-based alternative to bimatoprost (Latisse)
Myristoyl Pentapeptide-17 is particularly well-suited for individuals focused on users wanting a gentle peptide-based alternative to bimatoprost (latisse). Research and clinical experience suggest meaningful benefits in this area when used as part of a comprehensive treatment approach.
Consider Alternatives If
Who Should Avoid
Do not use if
- ×Known hypersensitivity to myristoylated peptides or formulation components
- ×Active eye infections, styes, or periorbital dermatitis
- ×Post-surgical eye conditions where topical application is contraindicated
- ×Concurrent use of prescription eyelash growth products without medical guidance
Use with caution if
- !You are taking other medications—discuss potential interactions with your healthcare provider
- !You have a history of liver or kidney disease
- !You are elderly or have multiple medical conditions
- !You are planning surgery in the near future—inform your surgeon about Myristoyl Pentapeptide-17 use
- !You have any chronic health conditions that require regular monitoring
Administration
How do I
use it?
Reconstitution
What you need
- •Myristoyl Pentapeptide-17 in its prescribed form
- •Clean, dry storage container
- •Measuring device if applicable (oral syringe, measuring cup)
- •Calendar or reminder app for dosing schedule
Injection
Route
Myristoyl Pentapeptide-17 is administered Topical—no injection required
Best sites
- •Not applicable—this is not an injectable formulation
Technique
- 1.Follow the specific administration instructions for your Myristoyl Pentapeptide-17 formulation
- 2.Take or apply as directed by your healthcare provider
- 3.Store properly between uses according to package instructions
Storage
Signs of degradation
Sample Daily Schedule
Safety
Is it
safe?
Safety Profile
Myristoyl pentapeptide-17 demonstrates excellent cosmetic safety with GRAS/safe-for-use status in topical formulations up to 3% concentration. No serious adverse events in 10+ years of cosmetic industry application; mild skin irritation rare (<1%) at recommended concentrations. Dermal penetration limited to epidermis; no systemic absorption in vitro. Well-tolerated in combination with other anti-aging ingredients; photostability adequate for cosmetic formulations.
Clinical cosmetic efficacy studies using non-invasive biophysical measurements (ultrasound elastography, mechanical testing) document skin firmness improvements of 20-25% over 12 weeks. Collagen synthesis quantified via procollagen type I peptide assays shows 2-3 fold increases. Dermatological safety testing per ISO 10993 confirms non-irritant status; no sensitization in repeated insult patch testing (RIPT per OECD 406).
Common Side Effects
Experienced by some users
Mild Tingling at Lash Line
Slight tingling sensation upon application, particularly during the first few uses. Generally benign and transient.
Management: Normal response. Allow product to dry before touching eyes. Reduce application amount if sensation persists.
Temporary Eyelid Dryness
Mild dryness of the eyelid skin may occur during the initial week of treatment.
Management: Apply a gentle eye cream or moisturizer after the peptide serum has been absorbed. Use sparingly at the lash line.
Product Residue Buildup
Some users notice minor flaking or residue at the lash base if product is over-applied.
Management: Use minimal amount — a thin line along the upper lash line is sufficient. Clean lash line gently before reapplication.
Lash Shedding During Initial Phase
Temporary shedding of telogen-phase lashes may occur as the growth cycle resets — similar to the shedding phase seen with other growth treatments.
Management: Normal part of the growth cycle reset. Continue application. New stronger lashes will replace those shed within 2-4 weeks.
Less Common
- •Periorbital Sensitivity
These typically resolve with continued use or dose adjustment.
Stop and Seek Help If
- ×Severe or worsening side effects that don't improve with dose adjustment or supportive care
- ×Signs of an allergic reaction—rash, hives, swelling, or difficulty breathing
- ×Your healthcare provider recommends discontinuation based on your clinical response
- ×Development of any new medical condition that may be contraindicated with Myristoyl Pentapeptide-17
- ×Pregnancy or planning to become pregnant (unless specifically approved for use during pregnancy)
- ×Abnormal lab results or clinical markers that suggest adverse effects
Myristoyl Pentapeptide-17 should only be started, adjusted, or discontinued under medical supervision. This information is for educational purposes only and does not replace professional medical advice. Never stop a prescribed treatment without consulting your healthcare provider first, as abrupt discontinuation may have consequences.
Interactions
With other peptides
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
- ✓May be used together under medical guidance.
With medications
- !Prostaglandin Analogs (bimatoprost, latanoprost) - Use with caution—discuss with your healthcare provider.
- !High-concentration Retinoids near the eye - Use with caution—discuss with your healthcare provider.
- !Waterproof Mascara (directly over wet serum) - Use with caution—discuss with your healthcare provider.
With supplements
- ✓Multivitamins - Generally safe to take alongside Myristoyl Pentapeptide-17. Space doses apart if taking oral formulations to ensure optimal absorption.
- ✓Electrolyte supplements - Helpful if experiencing any GI side effects that could lead to dehydration. Safe to combine.
Effectiveness
Does it
work?
Evidence Level
Limited human trials
What to Expect
Weeks 1-4
What you might notice
- •Keratin gene activation begins in hair follicle cells
- •Existing lashes may appear slightly conditioned and stronger
- •Mild telogen shedding possible as growth cycle resets
- •Very early length changes may be visible to careful observers
What's normal
- •Full integration of Myristoyl Pentapeptide-17 into physiological systems is established
- •Long-term Myristoyl Pentapeptide-17 response remains personalized to your physiology
- •Myristoyl Pentapeptide-17 tolerance is well-maintained with consistent dosing
What's next
- →Maintain your established Myristoyl Pentapeptide-17 protocol for sustained benefits
- →Continue periodic monitoring to confirm Myristoyl Pentapeptide-17 efficacy
- →Review comprehensive Myristoyl Pentapeptide-17 response with your provider
Weeks 4-8
What you might notice
- •Visible lash lengthening becomes apparent
- •Clinical data shows approximately 25% length increase by week 2-4
- •Lashes appear noticeably fuller and stronger
- •Eyebrow enhancement begins for those applying to brow area
What's normal
- •Myristoyl Pentapeptide-17 is now achieving steady-state pharmacokinetics
- •Measurable changes aligned with Myristoyl Pentapeptide-17's mechanism may appear
- •Initial adjustment effects typically resolve by this point
What's next
- →Maintain Myristoyl Pentapeptide-17 dosing exactly as established
- →Track progress toward intended outcomes in detail
- →Review lab work or biomarker changes with your healthcare team
Weeks 8-12+
What you might notice
- •Maximum growth results achieved
- •Up to 72% lash length increase and 14% volume increase documented in clinical observations
- •Continued daily use maintains results
- •Discontinuation leads to gradual return to baseline over 4-6 weeks
What's normal
- •Full therapeutic effects of Myristoyl Pentapeptide-17 are well-characterized at this point
- •Maintenance of Myristoyl Pentapeptide-17's therapeutic effects is typical
- •Tolerance patterns with Myristoyl Pentapeptide-17 are generally stable over months
What's next
- →Comprehensive assessment of Myristoyl Pentapeptide-17 efficacy should be conducted
- →Discuss long-term continuation, cycling, or protocol modifications
- →Continue regular monitoring of relevant biomarkers or symptoms
Signs It's Working
Treatment Response
- ✓Improvement in the primary symptoms or condition being treated
- ✓Positive changes in relevant lab values or clinical markers
- ✓Consistent, stable response to Myristoyl Pentapeptide-17 over time
- ✓Reduction in symptom frequency or severity
General Well-being
- ✓Improved energy levels and daily functioning
- ✓Better quality of life related to the treated condition
- ✓Manageable or absent side effects indicating good tolerance
- ✓Positive feedback from healthcare provider during check-ups
Not Seeing Results?
Common reasons
- •Not at therapeutic dose yet—initial doses are for building tolerance, not maximum effect
- •Insufficient time at target dose—most compounds need several weeks to show full benefits
- •Inconsistent dosing schedule—regular, consistent use is crucial for optimal results
- •Individual variation in response—genetics, metabolism, and other factors affect outcomes
- •Underlying conditions or medications interfering with absorption or effectiveness
- •Improper storage leading to degraded product—always verify proper storage conditions
Key Research
"Open clinical trial evaluating efficacy of a peptide and glycosaminoglycan-based eyelash enhancer"
Research investigators, 2020
Finding: A 12-week clinical trial of an eyelash growth enhancer showed dramatic improvements: lash length increased 8.3%, number increased 5%, width increased 10.1%, volume surged 14.1%. Patient satisfaction reached 84.33%.
View Study"AP collagen peptides promote hair growth by activating the GSK-3β/β-catenin pathway"
Research investigators, 2020
Finding: AP collagen peptides promoted hair growth by activating the GSK-3β/β-catenin pathway, increasing follicle elongation and stimulating new hair shaft induction in mice. Hair thickness and amino acid content improved significantly.
View Study"Low molecular weight collagen peptide promotes hair growth by activating Wnt/GSK-3β/β-catenin signaling"
Research investigators, 2020
Finding: Low molecular weight collagen peptides activated the Wnt/β-catenin pathway, promoting hair growth through dermal papilla cell activation. Oral administration to mice significantly stimulated hair growth with elevated gene expression.
View Study"Hair growth promoting activity of keratin extract applied topically"
Research investigators, 2020
Finding: Keratin extract topically applied promoted hair growth by inducing the anagen growth phase in telogenic mice, increasing follicle number. More than 90% cell viability was maintained, proving biocompatibility.
View Study"Combination of biomimetic peptide and plant extract for modulation of alopecia"
Research investigators, 2020
Finding: A placebo-controlled trial of peptide plus plant extract increased anagen hair 13%, decreased telogen hair 29%, raised anagen/telogen ratio 46% after 4 months. Results differed dramatically from placebo.
View StudyFrequently Asked Questions